Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted

Background: The MILES and ELVIS studies showed that vinorelbine is one of the best options for elderly patients with advanced non-small-cell-lung cancer (NSCLC). Oral vinorelbine at standard schedule (60-80 mg/m²/weekly) has good activity in terms of response rates and progression-free survival. In...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:In Vivo
Hlavní autoři: ROSSI, DAVID, LIPPE, PAOLO, ROCCHI, MARCO BRUNO LUIGI, SARTI, DONATELLA, CATALANO, VINCENZO, GRAZIANO, FRANCESCO, GIORDANI, PAOLO, BALDELLI, ANNAMARIA, FEDELI, STEFANO LUZI, IMPERATORI, LUCA, LAICI, GIANLUCA, CAPPELLETTI, CLAUDIA, TAMBURRANO, TIZIANA, BRACCI, RAFFAELLA, ALESSANDRONI, PAOLO
Médium: Artigo
Jazyk:Inglês
Vydáno: International Institute of Anticancer Research 2020
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7652434/
https://ncbi.nlm.nih.gov/pubmed/32871800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.12088
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky